Hormonal
Genetic factors, particularly polymorphisms affecting neurotransmitter systems (dopamine, serotonin) and metabolic traits (BMI, insulin resistance), significantly increase the risk of developing eating disorders, with distinct genetic architectures for anorexia nervosa versus binge-type disorders.
If you have a family history of eating disorders, you may have a biological predisposition. This is not your fault, but it is a risk factor you can manage. Focus on early identification of symptoms and seek professional support if you notice changes in eating habits or body image, as genetic risk can be mitigated by environmental factors.
Evidence of genetic risk factors for other EDs is growing... An individual is 11 times more likely to develop AN if they have a relative with the disorder... landmark 2019 study... found that both metabolic and anthropometric related genetic loci associated with BMI lowering alleles have strong correlations with AN
Why this rating
Based on large-scale genome-wide association studies and meta-analyses of thousands of participants.
Source
Risk factors for eating disorders: findings from a rapid review
Sarah Barakat et al. · Journal of Eating Disorders · 2023
DOI 10.1186/s40337-022-00717-4
More from this paper
- Childhood trauma, abuse, and neglect are strongly linked to the development of eating disorders, particularly Bulimia Nervosa and Binge Eating Disorder, through interactions with genetic susceptibility.Good
- Gut microbiota dysbiosis, specifically involving Escherichia Coli producing the CIpB protein, may contribute to eating disorder pathology by mimicking satiety hormones and triggering autoimmune reactions.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →